Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 749-757

  Scott, Julie ^a,b   Dorr, Robert T ^a,c   Samulitis, Betty ^a   Landowski, Terry H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c AmpliMed Corporation   (United States)

Author keywords

Combination chemotherapy; Drug interactions; Glutathione; Imexon; Synergy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIMETABOLITE; BORTEZOMIB; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IMEXON; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; NSC 714597; PACLITAXEL; PEMETREXED; PROTEASOME INHIBITOR; PYRIMIDINE DERIVATIVE; SULFORHODAMINE B; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; MYELOMA CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SCREENING ASSAYS, ANTITUMOR; HEXANONES; HUMANS; MELANOMA; MULTIPLE MYELOMA; TUMOR CELLS, CULTURED;

EID: 33947310585     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0329-z     Document Type: Article

References (45)

1. Adel AL, Dorr RT, Liddil JD (1993) The effect of anticancer drug sequence in experimental combination chemotherapy. Cancer Investig 11:15
2. Andrews PA, Murphy MP, Howell SB (1989) Characterization of cisplatin resistance in COLO 316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol 25:619
3. Arrick BA, Nathan CF (1984) Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 44:4224
4. Bedford P, Walker MC, Sharma HL, Perera A, McAuliffe CA, Masters J, Hill BT (1987) Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II). Chem Biol Interact 61:1
5. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J et al (1987) Characterization of a cis-diamminedichloroplatinum( II) resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414
6. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51:995
7. Camiener GW (1967) Studies of the enzymatic deamination of cytosine arabinoside-II. Biochem Pharmacol 16:1681
8. Capizzi RL, Keiser LW, Sartorelli AC (1977) Combination chemotherapy - theory and practice. Semin Oncol 4:227
9. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27
10. Correal P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G (2003) Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer 39:1547
11. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46:5125
12. DeVita VT, Young RC, Canellos GP (1975) Combinations versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98
13. Dorr RT, Liddil JD, Klien MK, Hersh EM (1995) Preclinical pharmacokinetics and antitumor activity of imexon. Investig New Drugs 13:113
14. Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S (2005) Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. Int J Gastrointest Cancer 36:15
15. Dragovich T, Gordon M, Mendeslon D, Wong L, Modiano M, Chow S, Samulitis B, O'Day S, Greiner K, Hersh E, Dorr R (2007) Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol (in press)
16. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT (2000) Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60:749
17. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT (2001) Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544
18. Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT (2002) Imexon activates an intrinsic apoptosis pathway in RPMI 8226 myeloma cells. Anticancer Drugs 13:1
19. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E (1999) Supraadditive effect of 2′.2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 44:117
20. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang W-H, Benstson AL, Soengas ME (2006) Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem 281:1107-1118
21. Frei E (1972) Combination cancer therapy: presidential address. Cancer Res 32:2593
22. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936
23. Goldin A (1980) Combined chemotherapy. Oncology 37:3
24. Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST (2003) Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol 31:271
25. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48(14):4024
26. Henderson EH, Samaha RJ (1969) Evidence that drugs in multiple combinations have materially advanced the treatment of human malignancies. Cancer Res 29:2272
27. Iyengar BS, Dorr RT, Remers WA (2004) Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem 47:218
28. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, Kato K (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin 23:422
29. Jenson LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235
30. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinnery CPN, McConkey DJ (2004) The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3:279
31. Knox RJ, Friedlos F, Lydall DA et al (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloro- platinum(II), and cis-diammine-(1,1-cyclobutanedicarboxylato)- platinum(II) differ only in the kinetics of their interactions with DNA. Cancer Res 46:1972
32. Leszczynska A, Pfaff E (1982) Activation by reduced glutathione of methotrexate transport into isolated rat liver cells. Biochem Pharmacol 31:1911
33. Liebmann JE, Hahn SM, Cook JA, Lipschulz C, Mitchell JB, Kaufman DC (1993) Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 53:2066
34. Micetich KC, Barnes D, Erickson LC (1985) A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1- cyclobutanedicarboxylato)-platinum(II) and cis- diamminedichloroplatinum(II) on L1210 cells. Cancer Res 45:4043
35. Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y, Imai K (2005) Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Cancer Ther Preclin 11:5248
36. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64:215
37. Park JS, Yamamoto W, Sekikawa T, Matsukawa M, Okamoto R, Sasaki M, Ukon K, Tanimoto K, Kumazaki T, Nishiyama M (2002) Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int J Oncol 20:333
38. Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10:3839
39. Richon VM, Schulte N, Eastman A (1987) Multiple mechanisms of cellular resistance to platinum coordination complexes. Cancer Res 47(8):2056
40. Roman NO, Fukushima S, Raymond MA, Landowski T, Dorr RT (2005) Imexon and gemcitabine are synergistic against human pancreatic cancer cells in vitro and in vivo. In: AACr 96th annual meeting, abst # 5884, vol 46, p 1385
41. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR (1990) Comparison of in vitro anticancer-drug- screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82:1113
42. Saunders PP, Schultz GA (1970) Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis. Biochem Pharmacol 19:911
43. Thrall BD, Raha GA, Springer DL, Meadows GG (1991) Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anticancer drugs. Pigment Cell Res 4:234
44. Wong SJ, Myette MS, Wereley JP, Chitambar CR (1999) Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clin Cancer Res 5:439
45. Zhou B, Mi S, Mo X, Shih J, Tsai J, Hu E, Hsu M, Kay K, Yen Y (2002) Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anitcancer Res 22:1369